Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

被引:0
|
作者
Reubi, Jean Claude [1 ]
Schär, Jean-Claude [1 ]
Waser, Beatrice [1 ]
Wenger, Sandra [1 ]
Heppeler, Axel [2 ]
Schmitt, Jörg S. [2 ]
Mäcke, Helmut R. [2 ]
机构
[1] Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland
[2] Department of Nuclear Medicine, Radiological Chemistry Division, University Hospital, Basel, Switzerland
关键词
Cell culture - Diagnosis - Gadolinium - Gallium - Nuclear medicine - Radioactive tracers - Tumors - Yttrium;
D O I
暂无
中图分类号
学科分类号
摘要
In vivo somatostatin receptor scintigraphy using Octreoscan is a valuable method for the visualisation of human endocrine tumours and their metastases. Recently, several new, alternative somatostatin radioligands have been synthesised for diagnostic and radiotherapeutic use in vivo. Since human tumours are known to express various somatostatin receptor subtypes, it is mandatory to assess the receptor subtype affinity profile of such somatostatin radiotracers. Using cell lines transfected with somatostatin receptor subtypes sst1, sst2, sst3, sst4 and sst5, we have evaluated the in vitro binding characteristics of labelled (indium, yttrium, gallium) and unlabelled DOTA-[Tyr3]-octreotide, DOTA-octreotide, DOTA-lanreotide, DOTA-vapreotide, DTPA-[Tyr3]-octreotate and DOTA-[Tyr3]-octreotate. Small structural modifications, chelator substitution or metal replacement were shown to considerably affect the binding affinity. A marked improvement of sst2 affinity was found for Ga-DOTA-[Tyr3]-octreotide (IC50 2.5 nM) compared with the Y-labelled compound and Octreoscan. An excellent binding affinity for sst2 in the same range was also found for In-DTPA-[Tyr3]-octreotate (IC50 1.3 nM) and for Y-DOTA-[Tyr3]-octreotate (IC50 1.6 nM). Remarkably, Ga-DOTA-[Tyr3]-octreotate bound at sst2 with a considerably higher affinity (IC50 0.2 nM). An up to 30-fold improvement in sst3 affinity was observed for unlabelled or Y-labelled DOTA-octreotide compared with their Tyr3-containing analogue, suggesting that replacement of Tyr3 by Phe is crucial for high sst3 affinity. Substitution in the octreotide molecule of the DTPA by DOTA improved the sst3 binding affinity 14-fold. Whereas Y-DOTA-lanreotide had only low affinity for sst3 and sst4, it had the highest affinity for sst5 among the tested compounds (IC50 16 nM). Increased binding affinity for sst3 and sst5 was observed for DOTA-[Tyr3]-octreotide, DOTA-lanreotide and DOTA-vapreotide when they were labelled with yttrium. These marked changes in subtype affinity profiles are due not only to the different chemical structures but also to the different charges and hydrophilicity of these compounds. Interestingly, even the coordination geometry of the radiometal complex remote from the pharmacophoric amino acids has a significant influence on affinity profiles as shown with Y-DOTA versus Ga-DOTA in either [Tyr3]-octreotide or [Tyr3]-octreotate. Such changes in sst affinity profiles must be identified in newly designed radiotracers used for somatostatin receptor scintigraphy in order to correctly interpret in vivo scintigraphic data. These observations may represent basic principles relevant to the development of other peptide radioligands. © Springer-Verlag 2000.
引用
收藏
页码:273 / 282
相关论文
共 50 条
  • [31] Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
    Jean Reubi
    Beatrice Waser
    Jean-Claude Schaer
    Jean A. Laissue
    European Journal of Nuclear Medicine, 2001, 28 : 836 - 846
  • [32] A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors
    Reubi, JC
    Schaer, JC
    Waser, B
    Hoeger, C
    Rivier, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 345 (01) : 103 - 110
  • [33] Different pathways of internalization of the somatostatin receptor sst3 and the possible autoreceptor sst1
    Roosterman, D
    Stevens, PA
    Meyerhof, W
    PEDIATRIC RESEARCH, 1999, 45 (04) : 97A - 97A
  • [34] Sexually dimorphic expression of sst1 and sst2 somatostatin receptor subtypes in the arcuate nucleus and anterior pituitary of adult rats
    Zhang, WH
    Beaudet, A
    Tannenbaum, GS
    JOURNAL OF NEUROENDOCRINOLOGY, 1999, 11 (02) : 129 - 136
  • [35] Different Pathways of Internalization of the Somatostatin Receptor sst3 and the Possible Autoreceptor sst1
    Dirk Roosterman
    Paul A Stevens
    Wolfgang Meyerhof
    Pediatric Research, 1999, 45 : 97 - 97
  • [36] Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst(1) and sst(2), in mouse fibroblast (Ltk(-)) cells
    Castro, SW
    Buell, G
    Feniuk, W
    Humphrey, PPA
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (04) : 639 - 646
  • [37] Localisation of somatostatin sst4 receptor protein in selected human brain areas; An immunohistochemical study
    Selmer, IS
    Schindler, M
    Humphrey, PPA
    Waldvogel, HJ
    Faull, RLM
    Emson, PC
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 472 - 472
  • [38] Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: A confocal microscopic study using novel fluorescent somatostatin derivatives
    Nouel, D
    Gaudriault, G
    Houle, M
    Reisine, T
    Vincent, JP
    Mazella, J
    Beaudet, A
    ENDOCRINOLOGY, 1997, 138 (01) : 296 - 306
  • [39] Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas
    Ramírez, JL
    Grant, M
    Norman, M
    Wang, XP
    Moldovan, S
    de Mayo, FJ
    Brunicardi, C
    Kumar, U
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 221 (1-2) : 105 - 119
  • [40] Immunohistochemical expression of somatostatin (SST) 2, 3 and 5 receptor subtypes in the cat trigeminocervical complex (TCC) and hypothalamus
    Classey, JD
    Levy, MJ
    Meeran, K
    Goadsby, PJ
    CEPHALALGIA, 2005, 25 (12) : 1204 - 1204